Palatin Technologies Inc. (PTN)

[seasonedwell]

That's a tough question.....

Several reasons...

1. The company is low on cash and there is a fear that they'll dilute.

2.Adam Feuerstein published an article saying "palatin's libido boosting drug failed frequency test" causing a panic sell on great results. Palatin reported positive results inline with FDA accepted endpoints. we need full investigation to be conducted on Adam's manipulation and lock him up.

https://www.change.org/p/sec-investigate-falsifying-article-on-ptn

3. Many investors are misunderstanding the potential here and some have equated and drawn comparisons to Addy.....They are wrong..

Last August it approved flibanserin (tradename: Addyi) for the estimated 5.5 to 8.6 million women in the U.S. believed to suffer from HSDD.

Is the HSDD population grossly overestimated? It is hard to tell from Addy. In many ways, it is a flawed drug. Unlike Viagra, its effects are not immediate. A patient needs to take it every day for weeks before the effects kick in. Second, the drug is saddled with side effects such as dizziness, low blood pressure, fainting and sleepiness; plus, it’s contraindicated with alcohol consumption. Add all this to the issue of modest efficacy, and it could be that women don’t believe Addyi’s benefit is worth the risks. It could well be that there is still a need for a drug to treat HSDD, but Addyi might not be the answer.


4. Warrants are most likely diluting the stock currently...